These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22044933)

  • 1. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.
    Koski A; Raki M; Nokisalmi P; Liikanen I; Kangasniemi L; Joensuu T; Kanerva A; Pesonen S; Alemany R; Hemminki A
    Mol Ther; 2012 Jan; 20(1):221-9. PubMed ID: 22044933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses.
    Gros A; Puig C; Guedan S; Rojas JJ; Alemany R; Cascallo M
    Mol Ther; 2010 May; 18(5):903-11. PubMed ID: 20179683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.
    Koski A; Bramante S; Kipar A; Oksanen M; Juhila J; Vassilev L; Joensuu T; Kanerva A; Hemminki A
    Mol Ther; 2015 Oct; 23(10):1641-52. PubMed ID: 26156245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
    Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.
    Downs-Canner S; Guo ZS; Ravindranathan R; Breitbach CJ; O'Malley ME; Jones HL; Moon A; McCart JA; Shuai Y; Zeh HJ; Bartlett DL
    Mol Ther; 2016 Aug; 24(8):1492-501. PubMed ID: 27203445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.
    Hemminki O; Diaconu I; Cerullo V; Pesonen SK; Kanerva A; Joensuu T; Kairemo K; Laasonen L; Partanen K; Kangasniemi L; Lieber A; Pesonen S; Hemminki A
    Mol Ther; 2012 Sep; 20(9):1821-30. PubMed ID: 22871667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.
    Kanerva A; Koski A; Liikanen I; Oksanen M; Joensuu T; Hemminki O; Palmgren J; Hemminki K; Hemminki A
    Mol Ther; 2015 Feb; 23(2):321-9. PubMed ID: 25381801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of oncolytic adenovirus and its application in cancer therapy.
    Liang Y; He J; Zhao Y
    Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
    Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
    J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus characterization: activity and immune responses.
    Gil-Hoyos R; Miguel-Camacho J; Alemany R
    Methods Mol Biol; 2014; 1089():117-32. PubMed ID: 24132482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.
    Raki M; Sarkioja M; Escutenaire S; Kangasniemi L; Haavisto E; Kanerva A; Cerullo V; Joensuu T; Oksanen M; Pesonen S; Hemminki A
    J Gene Med; 2011 May; 13(5):253-61. PubMed ID: 21520358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
    Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
    Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
    Kwon OJ; Kang E; Kim S; Yun CO
    J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.
    Czolk R; Schwarz N; Koch H; Schötterl S; Wuttke TV; Holm PS; Huber SM; Naumann U
    Int J Mol Med; 2019 Oct; 44(4):1484-1494. PubMed ID: 31432139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.
    Taipale K; Liikanen I; Koski A; Heiskanen R; Kanerva A; Hemminki O; Oksanen M; Grönberg-Vähä-Koskela S; Hemminki K; Joensuu T; Hemminki A
    Mol Ther; 2016 Aug; 24(7):1323-32. PubMed ID: 27039846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of targeted and armed oncolytic adenoviruses.
    Doronin K; Shayakhmetov DM
    Methods Mol Biol; 2012; 797():35-52. PubMed ID: 21948467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.